Central Bank & Trust Co. Has $1.46 Million Position in Zoetis Inc. (NYSE:ZTS)

Central Bank & Trust Co. reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 47.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,835 shares of the company’s stock after selling 8,009 shares during the period. Central Bank & Trust Co.’s holdings in Zoetis were worth $1,455,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares in the last quarter. Rakuten Securities Inc. increased its position in shares of Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 166 shares in the last quarter. Navigoe LLC bought a new stake in shares of Zoetis during the fourth quarter worth $30,000. Murphy & Mullick Capital Management Corp bought a new stake in shares of Zoetis during the fourth quarter worth $44,000. Finally, Asset Planning Inc bought a new stake in shares of Zoetis during the fourth quarter worth $58,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $170.15 on Friday. The firm has a 50-day moving average of $157.41 and a 200-day moving average of $164.29. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a market cap of $75.75 billion, a PE ratio of 31.11, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.20 billion. During the same quarter in the previous year, the company earned $1.38 EPS. The business’s revenue was up 1.4% on a year-over-year basis. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.18%. The ex-dividend date is Friday, July 18th. Zoetis’s dividend payout ratio is currently 35.91%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at $2,682,770. This trade represents a 2.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,188 shares of company stock valued at $367,289 in the last ninety days. 0.18% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ZTS. Piper Sandler raised their target price on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research report on Monday, May 12th. UBS Group cut their price target on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Stifel Nicolaus cut their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday, April 14th. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Finally, Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $212.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.